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Metabolic syndrome (MetS) is a chronic, multi-component disease characterised by central obesity, 
hyperglycaemia, dyslipidaemia, and hypertension. Since MetS leads to type 2 diabetes, cardiovascular 
disease, development of certain cancers, and eventually to premature death, it is not surprising that it draws 
the attention of scientists around the world. The aetiopathology of MetS is complex and still not fully 
understood. This review focuses on the role of endocrine factors such as cortisol and insulin in the 
development of MetS. It also takes a look at some of the contributing lifestyle and genetic factors as well 
as at the current knowledge about its treatment.
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Metabolic syndrome (MetS) is a modern disease 
characterised by the clustering of abnormalities such 
as central obesity, high levels of fasting glucose and 
triglyceride, low levels of high-density lipoprotein 
(HDL), and hypertension (1, 2). The prevalence of 
MetS has been increasing over the past two decades 
(1), and recent studies (3-5) suggest that it has reached 
25 % among the adults worldwide. Reports vary from 
21.9 % in men and 16.8 % in women in north-eastern 
Italy, and 24.6 % in alcohol-dependent male patients 
in north India to 31.25 % in rural women from 
Bangladesh. A small study on salt intake with 92 
participants in Croatia reports the prevalence of 
31.5 % (6). Among obese adolescents and pubertal 
children, the prevalence of MetS could be around 
15 %, judging by the reports of 14 % in Danish obese 
adolescents (7) and of 9.7 % to 41.2 % in obese 
pubertal children and 8.3 % to 34.2 % in obese pre-
pubertal children in Spain (8). The latter study makes 
a point that the prevalence of MetS depends on criteria 
used. Organisations such as the World Health 
Organization (WHO) and the American Heart 
Association and the National Heart, Lung, and Blood 
Institute (AHA/NHLBI) differ in diagnostic criteria 
for MetS (Table 1) (9-12). It is also evident that the 
prevalence of MetS increases with age; Novalletto et 
al. (3) reported the prevalence of 29.8 % in a group 
aged 60 to 69 years vs. 8.0 % in a group aged 30 to 
39. The aetiopathology of MetS is still unclear but is 
believed to be a combination of modern lifestyle, 
environmental factors, and heredity in some populations 
(2, 13). More importantly, patients diagnosed with 
MetS are at high risk of developing type 2 diabetes, 
cardiovascular disease, certain cancers, and of 
premature death (14-17).
The subtle interplay between MetS and hormones 
is well established. Adipose tissue, a hallmark of MetS, 
is not just inert reserve of fat, but an active endocrine 
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organ that plays an important role in the secretion of 
insulin and other hormones which regulate energy 
metabolism (18). In turn, many hormones and their 
receptors have important roles in regulating food 
intake, energy expenditure, and neuro-endocrine 
output of the pituitary gland and may contribute to the 
accumulation of fat.
The aim of this article is to give an overview of 
some of the most important endocrine, lifestyle, and 
genetic factors that are involved in the development 
of MetS. It also presents current knowledge on MetS 
treatment.
Endocrine factors and MetS
Cortisol is a glucocorticoid hormone secreted by 
the adrenal gland and is regulated by the 
adrenocorticotropic hormone (ACTH), whose 
secretion is, in turn, regulated by vasopressin and 
corticotrophin-releasing hormones, released by the 
hypothalamus. This complex set of hormone 
interactions is referred to as hypothalamic-pituitary-
adrenal (HPA) axis. Cortisol regulates energy 
metabolism through gluconeogenesis, but also affects 
processes such as inﬂ ammation (19, 20). Various 
cortisol-regulated physiological processes depend on 
glucocorticoid receptor (GR), which is activated upon 
cortisol binding (20, 21). On the pre-receptor level, 
cortisol action is additionally regulated by the 
in t race l lu la r  enzyme 11β-hydroxys te ro id 
dehydrogenase (11β-HSD) (20, 22, 23) that comes in 
two isoforms: type 1 (11β-HSD1) and type 2 (11β-
HSD2). Type 1 catalyses the conversion of the inactive 
form cortisone into active cortisol, while type 2 
converts active cortisol into its inactive form cortisone 
to lower the levels of active glucocorticoid and to 
inhibit cortisol activity (22, 24). Therefore, the level 
of cortisol in a particular tissue depends on blood 
cortisol levels produced by the adrenal gland and on 
tissue activity of 11β-HSD1 and density of GR (Figure 
1) (20, 21).
Higher cortisol levels in MetS patients suggest that 
cortisol contributes to the pathogenesis of MetS (22, 
25). Studies conducted so far (25, 26) indicate that 
higher HPA axis activity and cortisol level are 
associated with central obesity, but the nature of this 
relationship remains ambiguous. Grossniklaus et al. 
(26) associated higher body mass index (BMI) and 
higher morning salivary cortisol levels in middle-aged 
women with greater waist circumference (WC). Park 
et al. (25) found that higher cortisol level in Korean 
men and women was associated with increased risk 
of MetS, but since they found no association between 
cortisol and BMI or WC, the authors concluded that 
higher cortisol was associated with MetS regardless 
of overall adiposity. Mai et al. (27), however, observed 
a direct association between lipids and cortisol levels. 
They induced hyperlipidaemia in healthy young 
women of normal weight by treating them with 20 % 
lipid/heparin infusion and found higher serum cortisol 
than in controls (who received saline/heparin infusion). 
The authors concluded that hyperlipidaemia may 
increase adrenal sensitivity to ACTH, leading to 
greater cortisol release, such as in patients with MetS. 
This effect might contribute to disturbances along the 
HPA axis found in women with central obesity and 
impaired lipid metabolism.
It is important to note that cortisol secretion also 
depends on age and sex. In a study with untreated 
volunteers, Velhuis et al. (28) observed that cortisol 
secretion increased with age, especially in men, and 
that cortisol-ACTH feedback synchrony and ACTH-
cortisol feedforward synchrony declined with age and, 
again, were more pronounced in men. In addition, they 
observed that pulsatile and basal ACTH secretion and 
mean ACTH concentrations all increased with BMI 
and were higher in men than women. In other words, 
BMI also contributed to cortisol secretion.
We have already mentioned that cortisol action 
depends on the GR density and the activity of 11β-
HSD1 enzyme. According to a number of reports (19, 
22, 25) the visceral adipose tissue stores more GR than 
other fat depots and shows greater expression of 11β-
Figure 1  Intracellular action of cortisol depends on the 
conversion of cortisone to cortisol (and vice versa) 
by 11β-hidroxysteroid dehydrogenase (11β-HSD) and 
on its binding to glucocorticoid receptor (GR) 
(adapted from ref. 20). Isoform 11β-HSD type 1 
(11β-HSD1) converts inert cortisone to receptor-
active cortisol. Upon binding of cortisol to GR, GR 
is activated and can regulate the expression of genes 
involved in various physiological functions, including 
energy metabolism and inﬂ ammation.
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HSD1 in obese subjects (29, 30). Together with excess 
glucocorticoid secretion by the HPA axis (through 
increased peripheral glucocorticoidal signalling and 
cortisol reactivation) this may contribute to higher 
cortisol level observed in MetS.
Centrally distributed fat or central obesity is 
characteristic of MetS, and adipose tissue not only 
stores fat but works as an endocrine organ, as it 
produces pro-inﬂ ammatory cytokines (adipokines) 
such as tumour necrosis factor α (TNFα) and 
interleukin-6 (IL-6) (1, 23). In other terms, MetS is a 
state of chronic, low-grade inﬂ ammation (23). How 
does this explain the involvement of cortisol? Cortisol 
is released to stop tissue destruction and autoimmune 
processes. Classen (31) has reported that iatrogenic 
inﬂ ammation activates immunosuppressive cortisol 
response, which protects against type 1 diabetes and 
other autoimmune diseases, but causes type 2 diabetes, 
MetS, and obesity. Persistently high cortisol levels 
cause a number of adverse reactions, as they disrupt 
normal physiological functions. On the one hand, 
cortisol induces excessive glucose release from the 
liver, insulin resistance, free fatty acid release from 
adipocytes, and hypertension. On the other, it may 
chronically suppress immune reactions and anabolic 
processes in muscles. These changes increase the risk 
of MetS and other diseases such as morbid obesity, 
type 2 diabetes, infections, or endocrine disorders.
Fasting hyperglycaemia and/or insulin resistance 
and compensatory hyperinsulinaemia are the most 
important symptoms of MetS. Insulin resistance is the 
inability of insulin to act even though its secretion 
from β-cells is normal (18). In addition to its important 
role in energy metabolism, insulin affects cell growth 
and differentiation, as well as endothelial function. It 
is probably because of this variety of insulin action 
that MetS is able to affect it. For one, cortisol can 
interfere with insulin action by stimulating excessive 
hepatic gluconeogenesis, by inhibiting glycogen 
synthase in the muscles, and by promoting lypolisis 
in the adipose tissue (19, 22, 32). For two, central 
obesity can affect insulin action, as adipose tissue 
releases TNF-α, IL-6, and free fatty acids, which block 
normal insulin signalling pathway (2, 18). In addition, 
adiposity is characterised by low levels of adiponectin 
(a tissue-speciﬁ c circulating adipokine with insulin-
sensitising and anti-atherogenic properties), which 
contributes to systematic insulin resistance (18, 15, 
Table 1 Criteria for diagnosing the metabolic syndrome proposed by different organisations
PARAMETER WHOa AHA/NHLBIb IDFc EGIRd
Obesity (as WHRe, 
WCf or BMIg)
WHR>0.9 (m); 
WHR>0.85 (w); or 
BMI>30 kg m-2
WC≥102 cm (m); 
WC≥88 cm (w)
(ethnic values for WC 
recommended)
WC≥94 cm (m);
WC≥80 cm (w); or 
BMI>30 kg m-2
WC≥94 cm (m); 
WC≥80 cm (w)
Fasting glucose
≥6.1 mmol L-1 and/or 
impaired glucose 
tolerance
≥5.6 mmol L-1 or on 
therapy
≥5.6 mmol L-1 or DM
≥6.1 mmol L-1 
without DM
Blood pressure ≥140/90 mm Hg
≥130/85 mm Hg or 
on therapy
>130/85 mm Hg or 
on therapy
≥140/90 mm Hg or 
on therapy
HDL cholesterol
<0.9 mmol L-1 (m); 
<1 mmol L-1 (w)
<1.03 mmol L-1 (m); 
<1.3 mmol L-1 (w); or 
on therapy 
<1.03 mmol L-1 (m); 
<1.29 mmol L-1 (w); 
or on therapy 
<1 mmol L-1 or on 
therapy
Triglycerides ≥1.7 mmol L-1
≥1.7 mmol L-1 or on 
therapy 
≥1.7 mmol L-1 or on 
therapy









≥2 of any + insulin 
resistance and/or DM
≥3 of any criteria
≥2 of any + obesity 
(with ethnicity 
speciﬁ c values)
≥2 of any + insulin 
resistance 
aWHO - World Health Organization; bAHA/NHLBI - American Heart Association/National Heart, Lung, and Blood Institute; 
cIDF - International Diabetes Federation; dEGIR - European Group for the Study of Insulin Resistance;
eWHR - waist to hip ratio; fWC - waist circumference; gBMI - body mass index; (m)-men; (w)- women; DM-diabetes mellitus
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23). Long-term elevation of insulin levels causes 
desensitisation of insulin receptors, which in turn may 
lead to hyperglycaemia, smooth muscle hypertrophy, 
hypertension and many other physiological disorders 
(33).
One way in which hyperinsulinaemia leads to 
hypertension is by overstimulating the sympathetic 
nervous system through increased plasma noradrenaline 
levels, heart rate, renal sodium re-absorption, cardiac 
output, and peripheral resistance (34). There are 
several other mechanisms (such as the renin-
angiotensin-aldosterone system, mitogen-activated 
protein kinase pathway, increased levels of free fatty 
acids, and pro-inﬂ ammatory cytokines through which 
MetS (via insulin resistance and obesity) increases 
blood pressure (for review see 33).
Lifestyle factors and MetS
The release of hormones, including cortisol, 
follows a daily pattern we usually refer to as circadian 
rhythm. Normally, cortisol peaks in the early morning, 
keeps falling for the rest of the day, and troughs around 
midnight, only to rise quickly over the second half of 
the night (Figure 2). These circadian oscillations are 
controlled by the suprachiasmatic nucleus (SCN), a 
cluster of neurons in the hypothalamus, but also by 
peripheral oscillators that exist in most tissues of the 
body (35, 36). The internal biological clock is 
primarily aligned with the light/dark cycle, but is also 
affected by other factors such as locomotor activity 
and food intake (35-37). The circadian clock controls 
nearly all of the physiological and behavioural events 
in the body (36, 37). Any chronic misalignment 
between circadian rhythm and sleep or feeding can 
therefore lead to adverse metabolic and cardiovascular 
changes (38, 39). Modern lifestyle seems to be an 
epitome of this misalignment, as it usually implies 
physical inactivity, smoking, alcohol consumption, 
untimely feeding, and exposure to bright light over 
night. All these factors greatly contribute to the 
development of MetS. Here we shall focus on shift 
work, sleep deprivation, and stress.
Shift work can greatly disturb the circadian and 
behavioural rhythm and contribute to the development 
of obesity, diabetes, and cardiovascular disease. In a 
10-year follow-up study, Morikawa et al. (40) 
established a clear association between shift work and 
BMI (the highest increase in BMI was found in 
workers who transferred from daytime work to shift 
work). In another retrospective longitudinal study (41) 
covering the period between 1976 and 2007, night 
workers demonstrated not only signiﬁ cantly higher 
BMI, but also serum total cholesterol, triglycerides, 
and incidence of coronary heart disease than day 
workers. In yet another study, Manenschijn et al. (42) 
established higher BMI in shift workers and its 
correlation with higher cortisol levels in scalp hair and 
cardiovascular risk. Assessing several metabolic and 
endocrine parameters, Scheer at al. (38) found that 
experimental short-term circadian misalignment 
(similar to acute jet lag or chronic shift work) resulted 
in lower leptin, higher glucose, insulin, and mean 
arterial pressure, reduced sleep efficiency, and 
complete inversion of the cortisol behaviour across 
the circadian cycle. The authors conclude that a change 
in any of these parameters can trigger underlying 
mechanisms for MetS and cardiovascular disease. 
Cases in point, they argue, are the inversion of cortisol 
behaviour that can lead to insulin resistance and 
hyperglycaemia and lower leptin that can stimulate 
appetite and diminish energy expenditure.
Prolonged sleep deprivation is another predisposing 
factor for obesity, type 2 diabetes, and cardiovascular 
disease. In an eight-year follow-up study by Gangwisch 
et al. (43), short sleep (less than ﬁ ve hours a night) 
was associated with a signiﬁ cantly increased risk of 
hypertension. Since blood pressure drops 10 % to 
20 % in normotensive subjects during sleep, the 
authors concluded that the reason was the prolonged 
cycle of higher blood pressure, heart rate, sympathetic 
nervous system activity, physical and psychosocial 
stress, and increased salt retention associated with 
wakefulness. Vgontzas et al. (44) found a strong 
inverse correlation between sleep deprivation and WC. 
Several studies have shown that depriving healthy 
subjects of sleep can raise glucose and cortisol levels, 
Figure 2 Circadian rhythm of cortisol
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lower insulin sensitivity and leptin levels, and increase 
appetite (37). Kumari et al. (45) found that short sleep 
and sleep disturbances were independently associated 
with greater cortisol release, especially in the evening, 
which points to the deregulation of the feedback in 
the HPA axis. However, the speciﬁ c mechanisms and 
the involvement of the sympathetic nervous system 
and HPA axis remain to be elucidated.
Stress disorders such as depression and post-
traumatic stress disorder (PTSD) have also been 
associated with metabolic abnormalities, including 
obesity, dyslipidaemia, high blood pressure, and 
insulin resistance. Paslakis et al. (46) found that 
42.1 % of patients with major depression met the 
criteria for MetS diagnosis. Vogelzangs et al. (47) 
showed that depression led to increased visceral fat, 
independent of overall obesity. The same group of 
authors observed a synergistic relationship between 
depression, cortisol, and MetS and concluded that 
depression and high cortisol increase the odds for 
MetS (48). However, the association between 
depression and MetS could be a two-way street, that 
is, it could be MetS that leads to depression and not 
the other way around (49). Capuron et al. (50) claim 
that chronic low-grade inﬂ ammation pertinent to MetS 
can contribute to mood alterations. These ﬁ ndings 
raise the question whether the treatment of depression 
would positively reﬂ ect on MetS and vice versa, 
whether the treatment of MetS would relieve 
depression. Preliminary evidence suggests that anti-
depressant therapy (a four-week treatment with 
reboxetine) can have beneﬁ cial effects on several 
metabolic parameters, independent of treatment 
outcome, that can be attributed to the pharmacological 
proﬁ le of the drug (46). Vogelzangs et al. (51) showed 
that antidepressants act differently on inﬂ ammation. 
Tricyclic antidepressants, tetracyclic antidepressants, 
and serotonin-norepinephrine reuptake inhibitors 
stimulated inflammation level, whereas selective 
serotonin reuptake inhibitors inhibited it. Rege (52) 
demonstrated that ﬁ rst (chlorpromazine, zuclopenthixol, 
haloperidol, and triﬂ operazine) and second-generation 
antipsyhotics (clozapine, olanzapinme, risperidone, 
paliperidone, and quetiapine) stimulated gain weight. 
Weight gain can be a result of reduced resting energy 
expenditure. Blocking the histamine H1 receptor 
increases appetite, while serotonin 2C (2-HT2C) 
interaction with antipsychotics stimulates food intake 
despite satiety (53-55). A recent study (56) conﬁ rmed 
that users of tricyclic antidepressants were prone to 
obesity and dyslipidaemia and it associated low-grade 
inﬂ ammation with more severe anxiety disorders and 
depression.
Genetic factors and MetS
The central rhythm generator in mammals, SCN, 
receives light information from the retinal photoreceptor 
cells and transmits them as neuronal and/or humoral 
signals through the body (36). To keep this rhythm 
regular, the SCN needs Clock genes, which make up 
an auto-regulatory feedback loop by interacting with 
each other and generate circadian rhythms at the 
molecular level (36, 37, 57). Clock genes are expressed 
not only in the SCN and other locations in the brain, 
but also in the liver, heart, skeletal muscle, adipose 
tissue, and adrenal glands (35, 58). Peripheral Clock 
genes have their own intrinsic oscillatory systems that 
are regulated by the SCN (36, 59). However, peripheral 
clocks are capable of sustaining circadian rhythms 
even in the absence of SCN input and may therefore 
play an important role in regulating peripheral 
circadian rhythms of physiological processes (36, 37). 
Valenzuela et al. (59) found oscillatory expressions of 
Clock genes Per2 and Bmal1 in adrenal explants of 
an adult capuchin monkey, demonstrating that the 
primate adrenal gland has intrinsic capacity to 
maintain Clock gene oscillation. Also in that study, 
adrenal Clock gene expression was directly affected 
by the neurohormone melatonin, further conﬁ rming 
the independence of peripheral clocks. Gomez-
Abellan et al. (60) demonstrated Clock genes in human 
adipose tissue and their association with MetS. In the 
next study (61), the same authors conﬁ rmed that 
peripheral Clock genes (hPer2, hBmal1, and hCry1) 
in explants of adipose tissue in morbidly obese women 
oscillated accurately and independently of the SCN. 
They also observed that peripheral Clock genes 
controlled the timing of GR and 11β-HSD1 genes, and 
that this intracellular circadian clock could 
independently regulate peripheral cell functions.
We have mentioned earlier that the expression of 
the enzyme 11β-HSD1 is higher in the adipose tissue 
of obese subjects and that it increases the risk of 
obesity and MetS (22, 23). Gambinieri et al. (62) 
established a correlation between single nucleotide 
polymorphisms (SNPs) of HSD11B1, the gene 
encoding for enzyme 11β-HSD1, and type 2 diabetes, 
hypertension, and hyperandrogenism in women with 
the polycystic ovary syndrome (POCS). They studied 
two common SNPs (rs846910 and rs12086634) in 
HSD11B1 in a population of Southern European 
Caucasian women with and without PCOS and found 
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that regardless of PCOS, HSD11B1 alleles containing 
rs846910 A and rs12086634 T increased 11β-HSD1 
expression and activity (observed in higher 11β-HSD1 
mRNA levels in the adipose tissue and higher rates of 
appearance of an active cortisol during cortisol steady-
state infusion). To establish tissue-speciﬁ c cortisol 
proﬁ le in morbidly obese patients, Torrecilla et al. (63) 
investigated the mRNA expression of genes related to 
peripheral cortisol activity, including those coding for 
11β-HSD1, hexose-6-phosphate dehydrogenase 
(H6PDH),  GR,  and phosphoenolpyruvate 
carboxykinase (PEPCK) in the liver, visceral, and 
subcutaneous adipose tissues in morbidly obese 
patients with and without MetS. In the liver, mRNA 
expression of the tested genes was higher in patients 
with MetS and positively correlated with a number of 
clinical characteristics of MetS. Interestingly, those 
genes were not differently expressed in the visceral 
and subcutaneous adipose tissues between the groups. 
The authors therefore attributed liver-speciﬁ c up-
regulation of genes involved in peripheral cortisol 
activity and consequent hepatic hypercortisolism to 
MetS.
Other studies found that the adipose tissue had a 
higher frequency of genes coding for adipokines than 
other tissues (13, 64). Moreover, visceral adipose 
tissue had 30 % of these genes whereas the subcutaneous 
adipose tissue had 20 % (13, 65).
One adipokine that highly increases the risk of 
thrombotic diseases is plasminogen activator inhibitor 
type 1 (PAI-1). Mertens et al. (66) found a strong 
correlation between its plasma levels and visceral 
adiposity. Matzusawa (64) found a tenfold increase in 
PAI-1 mRNA in animal visceral adipose tissue during 
fat accumulation while its level in subcutaneous 
adipose tissue remained unchanged. Funahashi et al. 
(15), in turn, investigated the genetic reasons 
underlying the lowering of plasma levels of adiponectin, 
adipokine that protects against insulin resistance and 
atherosclerosis, in MetS patients. What lowered 
adiponectin levels was the missense mutation of the 
adiponectin gene, with the substitution of isoleucine 
164 to threonine in the globular domain. Subjects 
carrying this mutation were frequently hypertensive, 
hyperlipidemic, diabetic, and had atherosclerotic 
vascular diseases.
Studies (67, cf. 68) on separated twins and adopted 
children, designed to compare environmental and 
genetic inﬂ uences, showed that obesity was inherited 
by between 40 % and 70 % of the participants. 
Ramachandrappa and Farooqi (68) report that by 
genotyping between 350,000 and 500,000 SNPs 
covering more than 75 % of the human genome, 
genome-wide association studies identiﬁ ed more than 
20 genetic loci relevant for body weight regulation.
Other researchers (22, 69) have reported that 
maternal diet, growth during early foetal development, 
and low birth weight are independently associated 
with the increased risk of MetS in adult life. In a study 
on nonhuman primates (70), exposure of pregnant 
mothers (regardless of whether they were lean or 
obese) to a high-fat diet led to a number of changes 
in liver metabolism in their offspring that increase the 
risk of metabolic diseases. The reader may ask how 
this is related to genetic predisposition. According to 
Sebert et al. (69), changes in maternal diet or in uterine 
blood supply near the term can result in cellular stress 
in the offspring and can modify genes that control 
DNA methylation. In other words, maternal diet can 
set off the phenotypes prone to the development of 
metabolic diseases (69). However, we still do not 
understand how maternal diet affects DNA 
modiﬁ cations and how this interaction triggers the 
development of metabolic diseases.
Treatment of MetS
Current therapy of choice for patients diagnosed 
with MetS is to change their lifestyle by increasing 
physical activity and improving dietary habits. De 
Souza Leao et al. (71) compared 15 studies with 
different approach to the treatment of MetS. Some 
investigated normocaloric diet alone, some 
normocaloric diet combined with exercise, some low-
calorie diet combined with exercise, and some low-
calorie diet alone. The best results were obtained with 
the combination of low-calorie diet and exercise.
Pharmacological treatment of MetS seeks to target 
a number of speciﬁ c factors that lead to the disease. 
On the one hand, this diversity of factors provides 
many options for drug development, but on the other, 
diversiﬁ cation encourages partial approach that may 
not address the complex nature of the disease as 
efﬁ ciently as one hopes for.
One promising specific-target approach is the 
inhibition of the 11β-HSD1 enzyme in order to 
normalise cortisol (21, 22). Studies on animals and 
humans have shown that pharmacological inhibition 
of 11β-HSD1 activity has favourable metabolic 
(reduction of glucose level, insulin resistance, and 
dyslipidaemia) and anti-inﬂ ammatory effects (22, 23, 
72). A large number of chemical classes have been 
identiﬁ ed as potent and selective small-molecule 
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inhibitors of 11β-HSD1 (73, 74, cf. 75). This ﬁ nding 
is important since 11β-HSD1 could be a valid 
therapeutic target not only for obesity and MetS, but 
also for other comorbidities, such as type 2 diabetes 
(21, 72).
Currently, MetS is pharmacologically managed by 
treating its components: obesity, diabetes, hypertension, 
and hyperlipidaemia. At the moment, the only 
registered pharmaceutical for the treatment of obesity 
through removal of fat tissue, a major component of 
MetS, is orlistat. Orlistat inhibits pancreatic lipase, 
and by preventing the hydrolysis of triglyceride esters 
to free fatty acids and triglyceride, prevents their 
gastrointestinal absorption (76). Registered antidiabetic 
drugs include derivates of sulfonylurea, glinides, and 
acarbose, which all lower blood glucose (77, 78). 
Metformin, a biguanide-type antidiabetic agent, can 
induce weight loss, and has recently become the ﬁ rst 
choice in diabetes type 2 treatment in patients with 
MetS (79). Hypertension, another component of MetS, 
is treated with anti-hypertensive drugs. There are 
several groups of antihypertensives that are successfully 
used in practice, such as diuretics, sympatholitic drugs, 
vasodilators, and angiotensin-converting enzyme 
(ACE) inhibitors (80). Some of them, such as ACE 
inhibitors, central acting antihypertensives, and 
antagonists of α1-adrenoreceptors, have also shown 
beneficial effects against insulin resistance (81). 
Atherogenic dyslipidaemia is usually treated with 
statins, which target hypercholesterolaemia, and with 
ﬁ brates or derivatives of nicotinic acid, which target 
hypertriglyceridaemia (82).
CONCLUSION
The prevalence of MetS has reached epidemic 
proportions and the number of patients rises 
exponentially. Its aetiology is still unclear, but research 
has identified a number of aetiological and 
pathophysiological factors and lifestyle triggers. These 
predisposing factors can be genetic or environmental 
and persist throughout our life (from foetal development 
to adult age). Since MetS is associated with diabetes 
type 2, cardiovascular disease, and certain cancers and 
signiﬁ cantly diminishes the quality of life and life 
expectancy, an early recognition and prevention, 
where possible, is extremely important. Because of 
known comorbidities of MetS including Cushing’s 
syndrome, PCOS, and depression, treatment should 
focus on the management of these conditions and 
improvement of MetS symptoms.
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Sažetak
ENDOKRINI I GENETIČKI ČIMBENICI TE ŽIVOTNE NAVIKE KOJI PRIDONOSE NASTANKU 
METABOLIČKOG SINDROMA
Metabolički sindrom (MetS) kronična je višekomponentna bolest, koju karakteriziraju abdominalna debljina, 
hiperglikemija, dislipidemija i hipertenzija. Kako MetS dovodi do razvoja šećerne bolesti tipa 2, 
kardiovaskularnih i nekih malignih bolesti te posljedično do prerane smrti, ne čudi da MetS privlači 
pozornost znanstvenika diljem svijeta. Etiopatologija MetSa je kompleksna te još nije u potpunosti 
razjašnjena. Cilj je ovoga rada dati literaturni pregled uloge nekih endokrinih poremećaja, kao što su 
poremećaj kortizola i inzulina, u razvoju MetSa. Također, razmatrani su i neki faktori načina života/životnog 
stila te genetički faktori koji pridonose razvoju MetSa. Na kraju su spomenuta trenutačna saznanja u 
liječenju MetSa i njegovih komponenti. 
KLJUČNE RIJEČI: cirkadijalni ritam, hiperglikemija, hipertenzija, inzulin, kardiovaskularne bolesti, 
kortizol, MetS, šećerna bolest
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